Washington Post reports regrets among users of unregulated peptides
The paper collects accounts from people who bought gray-market peptides online and later questioned the purchases.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 13 06:31 ETSource: The Washington Post
The wire
- 01The Washington Post reports on people who used hyped, unregulated peptides sold outside approved channels and say they regret it.
- 02Clinicians and telehealth operators face patients citing mainstream coverage of gray-market peptide risks when asking about BPC-157 and similar compounds.
- 03The piece is anecdotal reporting rather than a safety study, so the scale of harm across the gray market remains unquantified.
From the source
Read at washingtonpost.comPeople who have taken hyped, unregulated peptides have regrets
